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CASE REPORT
Utilizing fractional resurfacing in the treatment of therapy-resistant
melasma
ZEINA S. TANNOUS1,2 & SUSANNE ASTNER1
1Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, and
2Wellman Center of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Abstract
Background. Multiple treatment modalities have been employed for the management of melasma with minimal to no
success.
Objective. We propose fractional resurfacing as a new treatment modality for melasma.
Methods. A 31-year-old Caucasian female with facial epidermal and dermal melasma, resistant to multiple courses of topical
therapies, was treated with two sessions of full-face fractional resurfacing (FraxelTM Laser; Reliant technologies, San Diego,
CA), separated by a three-week interval. Clinical improvement was assessed by Wood’s Lamp examination as well as
parallel and cross-polarized comparative photography at baseline and 6 months later.
Results. Marked reduction in epidermal and dermal facial pigmentation was observed at the six-month follow-up visit.
Conclusion. Fractional resurfacing may prove to be an effective and safe treatment modality for lightening of the epidermal
and dermal pigmentation of melasma. Further studies with long-term follow-up periods and multiple patients with diverse
skin phototypes and different variants of melasma are warranted
Key words: Laser treatment, melasma
Introduction
Melasma, also known as chloasma and the ‘mask of
pregnancy’, is an acquired brown macular hyperpig-
mentation, usually of the face. It is nine times more
common in females than males. Melasma usually
presents bilaterally and symmetrically on the face,
but extensor forearms may also be involved. Sun
exposure, pregnancy and oral contraceptive pills
have all been associated with its presentation.
There are three types of melasma including:
epidermal, dermal and mixed variants.
The pathogenesis of this common skin disorder
remains unknown, and various therapeutic modal-
ities have been employed with minimal to no success
(1).
Fractional resurfacing (FR) is a new concept of
skin rejuvenation that produces a unique thermal
damage pattern (2). FR produces multiple columns
of thermal damage, referred to as microthermal
treatment zones (MTZ), and characteristically
spares the tissue surrounding each column. The
histology of a microthermal treatment zone (MTZ)
shows homogenization of dermal matrix and the
formation of microscopic epidermal necrotic debris
(MEND) (2). MENDs are thought to represent the
elimination of the damaged epidermis containing
the pigment in the basal cell layer facilitated by the
movement of the rapidly migrating viable keratino-
cytes present at the wound margins. This process
might explain why FR might provide a promising
modality in the treatment of melasma. We present a
patient with therapy-resistant melasma treated with
two sessions of FR and her follow-up at 6 months.
Case presentation
We present a 31-year-old Caucasian female,
Fitzpatrick skin phototype II–III, with centrofacial
and malar melasma that was treated successfully
with fractional resurfacing.
Patient’s past medical history was significant for
moderate sun exposure with multiple blistering
sunburns. She was never pregnant. At age 22, she
began a one-year course of oral contraceptives. Her
melasma initially presented at 23 years of age and
persisted, with minimal fading during winter
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months. Prior to treatment with FR, the patient had
been treated with multiple courses of topical
therapies, including 4% hydroquinone cream, treti-
noin cream, as well as TrilumaH cream (fluocinolone
acetonide 0.01%, hydroquinone 4%, tretinoin
0.05%), in combination with strict sun protection
and daily application of SPF 30 sunscreen, with only
mild to no improvement.
Physical examination revealed a light to dark
brown symmetric macular hyperpigmentation in a
centrofacial and malar distribution (Figure 1a–c,
Figure 2a–c). Wood’s light examination revealed
partial accentuation of the epidermal pigmentary
component. Other areas revealed a brown-gray color
suggestive of mixed epidermal and dermal melasma.
There was no history suggestive of post-inflamma-
tory hyperpigmentation, exogenous ochronosis or
drug-induced hyperpigmentation.
The patient underwent two treatments with the
fractional resurfacing laser (FraxelTM Laser; Reliant
technologies, San Diego, CA) to her full face,
separated by a three-week period (September and
October 2004).
Prior to each treatment, the face was cleansed with
soap and water, scrubbed with aluminum chloride
crystals and wiped with alcohol. The skin was
allowed to dry and FD&C1 water-soluble blue tint
was painted on the treatment areas. One hour before
the procedure for local anesthesia, 30% topical
lidocaine ointment was applied. Treatment was
performed at energy settings between 6 mJ and
8 mJ, and a density setting of 250 MTZs/cm2. Eight
passes were delivered with appropriate overlap to a
total density of 2000 MTZ/cm2. After each proce-
dure, the face was cleansed, and mild to moderate
erythema, resembling a sunburn reaction, was
observed. The erythema resolved in 2 days and
was easily covered with makeup. It was then
replaced with mild bronzing that lasted 2–3 days.
The patient experienced no significant swelling. She
reported marked improvement in her melasma one
week after each treatment. She was seen in follow-up
6 months after her first treatment where she
demonstrated marked resolution of her melasma
(Figure 1d–f, cross-polarized images; Figure 2d–f,
parallel-polarized images).
Discussion
Melasma is an acquired brown macular hyperpig-
mentation of the face that is cosmetically displeasing
to many patients. Melasma treatment can be
frustrating and often ineffective. Dermal and
mixed-type melasma are least responsive to therapy.
For all melasma patients, sunscreen and sun
avoidance are essential components of therapy.
There are multiple topical and laser therapies that
can be employed for treatment. Topical treatments
include bleaching agents such as hydroquinone,
topical tretinoin, and azeleic acid. A combination
therapy of fluocinolone acetonide 0.01%, hydroqui-
none 4%, tretinoin 0.05% (Tri-Luma Cream) (3),
can produce favorable clinical results with decreased
irritation. Chemical peels, including Jessner’s solu-
tion, glycolic acid peels as well as trichloroacetic acid
peels, can also be used with variable clinical results
(4,5).
Laser treatment for melasma is not usually
recommended given its high incidence of post-
inflammatory hyperpigmentation and its modest
efficacy (6,7). Q-switched ruby and Q-switched
Nd:YAG lasers are both slightly to moderately
effective in treating melasma; however, they both
have a high incidence of pigmentary alterations after
treatment. In cases refractory to topical creams and
chemical peels, Erbium:YAG (8) and carbon dioxide
lasers can produce significant improvement in the
melasma but are often complicated with post-
inflammatory hyperpigmentation. There is a need
for less invasive and effective modalities with lower
incidence of side effects.
We present, to our knowledge, the first reported
case of therapy-resistant melasma treated success-
fully with FR. The patient has suffered from
centrofacial and malar melasma for 9 years, which
was resistant to long-term use of multiple courses of
topical medications including hydroquinone and
tretinoin, coupled with extensive sun protection.
She received two sessions of FR treatments in a
3-week interval. The patient demonstrated remark-
able and persistent resolution of her melasma at
her 6 months follow-up examination (Figures 1
and 2).
FR is a novel concept of skin rejuvenation that has
the potential to treat a variety of epidermal and
dermal conditions. It produces a unique thermal
damage pattern. In contrast to ablative skin resurfa-
cing and nonablative skin resurfacing, which achieve
homogenous thermal damage at particular depth,
FR creates microscopic thermal wounds, referred to
as MTZs (2). FR specifically spares tissue surround-
ing each MTZ, thus allowing rapid re-epithelializa-
tion and fast epidermal repair due to the small size of
the wounds and short migratory paths for keratino-
cytes. Examination of the histology of MTZs shows
homogenization of dermal collagen and the forma-
tion of MENDs containing melanin (2). MENDs
result from the elimination of the damaged kerati-
nocytes with their pigment content, facilitated by the
movement of the rapidly migrating viable keratino-
cytes present at the wound margins. This hypothesis
might provide a partial explanation to why FR might
prove helpful in the treatment of epidermal mel-
asma. As to the dermal component of melasma, FR
might induce disruption of the dermal macrophages
containing melanin, releasing melanin granules into
the dermis and changing their optical properties.
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Figure 1. Clinical photographs taken with a cross-polarized digital imaging system. Left panel taken at baseline; 1(a) frontal image, 1(b) left
face image and 1(c) right face image. Right panel taken 6 months later; 1(d) frontal image, 1(e) left face image 1(f) right face image. Note
the marked resolution of the mixed variant melasma, detected more readily with cross-polarized light.
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Figure 2. Clinical photographs taken with a parallel-polarized digital imaging system. Left panel taken at baseline; 2(a) frontal image, 2(b)
left face image and 2(c) right face image. Right panel taken 6 months later; 2(d) frontal image, 2(e) left face image 2(f) right face image.
Note the marked resolution of the mixed variant melasma.
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This might be manifested clinically as lightening of
the dermal component of melasma.
Conclusion
We present a case of a young female with recalcitrant
melasma treated successfully with fractional resurfa-
cing. We believe that this is a novel, effective and
safe treatment for the removal of epidermal and
dermal pigmentation associated with therapy-resis-
tant melasma. Long-term follow-up and histological
studies are needed to corroborate our findings.
Based upon our findings, further studies with
multiple patients, diverse skin phototypes, and
different variants of melasma are warranted.
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